Trials / Completed
CompletedNCT00320021
Effect of Pyridorin in Patients With Diabetic Nephropathy
A Randomized, Double-Blind, Placebo-Controlled, Escalating Dose, Pilot Study to Evaluate the Safety, Tolerability and Biologic Activity of Pyridorin (Pyridoxamine Dihydrochloride) in Patients With Diabetic Nephropathy Associated With Type 1 or Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (planned)
- Sponsor
- BioStratum · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to evaluate the safety, tolerability and efficacy of Pyridorin (pyridoxamine dihydrochloride) up to 250 mg given orally twice daily in patients with diabetic kidney disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pyridorin (pyridoxamine dihydrochloride) |
Timeline
- Start date
- 2002-07-01
- Completion
- 2003-09-01
- First posted
- 2006-04-27
- Last updated
- 2006-04-27
Source: ClinicalTrials.gov record NCT00320021. Inclusion in this directory is not an endorsement.